Wayshine Biopharm, Inc.
Clinical trials sponsored by Wayshine Biopharm, Inc., explained in plain language.
-
New hope for lung cancer patients when standard drugs fail
Disease control Recruiting nowThis study is testing whether adding a new experimental drug called WSD0922-FU to an existing lung cancer medication (osimertinib) is safe and can help control advanced non-small cell lung cancer. It is for patients whose cancer has spread or has developed specific genetic change…
Phase: PHASE1, PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug trial targets lung Cancer's resistance to leading treatment
Disease control Recruiting nowThis study is testing an experimental drug called WSD0922-FU for people with advanced non-small cell lung cancer. It is for patients whose cancer has started growing again after initial treatment with the drug osimertinib and who have a specific genetic change (C797S mutation) in…
Phase: PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated Mar 03, 2026 14:06 UTC